GlassScriptPhysician profile
Brent A Wakefield
NPI 1447334206
$2,419.55
in general payments reported to CMS, 2019-2025
36 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $223 · 2021: $227 · 2022: $497 · 2023: $462 · 2024: $401 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.59 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $216.15 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $197.00 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $194.62 | 2022-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $177.93 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $159.51 | 2019-2024 | |
| Pfizer INC. | $135.01 | 2019-2025 | |
| Lilly USA, LLC | $85.83 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $73.30 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $63.76 | 2023 | |
| Vanda Pharmaceuticals INC. | $61.91 | 2025 | Fanapt |
| Amgen INC. | $49.24 | 2021-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $49.16 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $48.04 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $46.06 | 2022-2023 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $39.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $38.09 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $35.35 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $35.11 | 2021 | |
| Corium, LLC | $24.83 | 2023 | Adlarity |
| Boston Scientific Corporation | $24.80 | 2022 | |
| Lundbeck LLC | $21.34 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $20.97 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.55 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $19.25 | 2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.17 | 2024 | Caplyta |
| Medtronic, INC. | $19.12 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $18.99 | 2022 | |
| Ucb, INC. | $18.30 | 2020 | |
| Shire North American Group INC | $18.17 | 2019 | |
| Exact Sciences Corporation | $16.31 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $14.13 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.20 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.73 | 2023 | |
| Horizon Therapeutics Plc | $12.53 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Wakefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.